Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 5
Submit an article Journal homepage
164
Views
8
CrossRef citations to date
0
Altmetric
Reviews

The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence

Mo YangProgram in Personalized Medicine & Targeted Therapeutics, University of the Sciences, Philadelphia, 600 S. 43rd St., Philadelphia, PA, USACorrespondence[email protected]
,
Dhaval S PatilProgram in Personalized Medicine & Targeted Therapeutics, University of the Sciences, Philadelphia, 600 S. 43rd St., Philadelphia, PA, USA
,
Waqas TufailProgram in Personalized Medicine & Targeted Therapeutics, University of the Sciences, Philadelphia, 600 S. 43rd St., Philadelphia, PA, USA
&
Amalia M IssaProgram in Personalized Medicine & Targeted Therapeutics, University of the Sciences, Philadelphia, 600 S. 43rd St., Philadelphia, PA, USA;Department of Health Policy and Public Health, University of the Sciences, Philadelphia, 600 S. 43rd St., Philadelphia, PA, USACorrespondence[email protected]
Pages 597-611 | Published online: 09 Jan 2014

References

  • Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J. Clin. 63, 11–30 (2013).
  • Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010–2020. J. Natl Cancer Inst. 103, 1–12 (2011).
  • Tangka FK, Trogdon JG, Richardson LC et al. Cancer treatment cost in the United States: has the burden shifted over time? Cancer 116(14), 3477–3484 (2010).
  • Yabroff KR, Lund J, Deanna Kepka D et al. Economic burden of cancer in the United States: Estimates, projections, and future research Cancer Epidemiol. Biomarkers Prev. 20, 2006–2014 (2011).
  • Elkin EB, Bach PB. Cancer's next frontier: addressing high and increasing costs. JAMA 303, 1086–1087 (2010).
  • Flockhart D, Skaar T, Berlin D, Klein T, Nguyen A. Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. 86(1), 109–113 (2009).
  • Deverka PA, Vernon J, McLeod HL. Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 50, 423–437 (2010).
  • Bradbury PA, Tu D, Seymour L et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J. Natl Cancer Inst. 102(5), 298–306 (2010).
  • Perez-Ellis C, Goncalves A, Jacquemier J et al. Cost-effectiveness analysis of trastuzumab (Herceptin) in HER2-overexpressed metastatic breast cancer. Am. J. Clin. Oncol. 32(5), 492–497 (2009).
  • Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer. 115(17), 3858–3867 (2009).
  • Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost–effectiveness analysis. Ann. Oncol. 16(6), 909–914 (2005).
  • Norum J, Olsen JA, Wist EA, Lønning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol. 46(2), 153–164 (2007).
  • Morelle M, Haslé E, Treilleux I et al. Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int. J. Technol. Assess Health Care 22(3), 396–401 (2006).
  • Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976–1997. Ann. Intern. Med. 132(12), 964–972 (2000).
  • Ramsberg J, Odeberg S, Engström A, Lundin D. Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. The first year. Eur. J. Health Econ. 5(4), 351–356 (2004).
  • Au F, Prahardhi S, Shiell A. Reliability of two instruments for critical assessment of economic evaluations. Value Health 11(3), 435–439 (2008).
  • Chiou CF, Hay JW, Wallace JF et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med. Care 41(1), 32–44 (2003).
  • Foster WJ, Tufail W, Issa AM. The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidence. Br. J. Ophthalmol. 94(9), 1118–1126 (2010).
  • Gerkens S, Crott R, Cleemput I et al. Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity. Int. J. Technol. Assess. Health Care 24(3), 318–325 (2008).
  • Spiegel BM, Targownik LE, Kanwal F et al. The quality of published health economicanalyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterol. 127(2), 403–411 (2004).
  • Peterson LE, Goodman C, Karnes EK, Chen CJ, Schwartz JA. Assessment of the quality of cost analysis literature in physical therapy. Phys. Ther. 89(8), 733–755 (2009).
  • Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genet. Med. 7(8), 519–523 (2005).
  • Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomic 28(11), 1001–1013 (2010).
  • Wade VA, Karnon J, Elshaug AG, Hiller JE. A systematic review of economic analyses of telehealth services using real time video communication. BMC Health Serv. Res. 10, 233 (2010).
  • Sonnenberg FA, Beck JR. Markov models in medical decision-making: a practical guide. Med. Decis. Making 13(4), 322–338 (1993).
  • Briggs A, Sculpher M, Claxton K. Decision modeling for health economic evaluation. Oxford University, New York, NY, USA, 439–451 (2006).
  • Green C. Modeling disease progression in Alzheimer's disease: a review of modeling methods used for cost-effectiveness analysis. Pharmacoeconomic 25(9), 735–750 (2007).
  • Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int. J. Technol. Assess Health Care 26(3), 330–333 (2010).
  • Bell CM, Urbach DR, Ray JG et al. Bias in published cost effectiveness studies: systematic review. BMJ 332(7543) 699–703 (2006).
  • Saltelli A, Ratto M, Andres T et al. Global Sensitivity Analysis. The Primer. John Wiley & Sons, England (2008).
  • Ofman JJ, Sullivan SD, Neumann PJ et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. 9(1), 53–61 (2003).
  • Barrow E, McMahon R, Evans DG, Levine E, Hill J. Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. Br. J. Surg. 95(7), 868–875 (2008).
  • Mancl EE, Kolesar JM, Vermeulen LC. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Am. J. Health Syst. Pharm. 66(23), 2105–2112 (2009).
  • Mittmann N, Au HJ, Tu D et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J. Natl Cancer Inst. 101(17), 1182–1192 (2009).
  • Blank PR, Schwenkglenks M, Moch H, Szucs TD. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res. Treat. 124(2), 497–507 (2010).
  • Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health 12(Suppl. 3), S82–S84 (2009).
  • Dahlberg L, Lundkvist J, Lindman H. Health care costs for treatment of disseminated breast cancer. Eur. J. Cancer 45(11), 1987–1991 (2009).
  • Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 176(10), 1429–1434 (2007).
  • Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol.22(5), 854–863 (2004).
  • Essers BA, Seferina SC, Tjan-Heijnen VC et al. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. Value Health 13(4), 375–380 (2010).
  • Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110(3), 489–498 (2007).
  • Garrison LP Jr, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health 12(8), 1118–1123 (2009).
  • Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am. J. Manag. Care 11(5), 313–324 (2005).
  • Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4), 381–387 (2010).
  • Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res. Treat. 112(1), 175–187 (2008).
  • Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.25(6), 625–633 (2007).
  • Lidgren M, Jönsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann. Oncol. 19(3), 487–495 (2008).
  • Lidgren M, Wilking N, Jönsson B, Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol. 47(6), 1018–1028 (2008).
  • Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109(6), 1011–1018 (2007).
  • Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomic 25(5), 429–442 (2007).
  • Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann. Oncol.17(3), 381–390 (2006).
  • Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 87(2), 146–159 (2008).
  • Neyt MJ, Albrecht JA, Clarysse B, Cocquyt VF. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int. J. Technol. Assess Health Care 21(1), 132–137 (2005).
  • Oestreicher N, Ramsey SD, Linden HM et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet. Med. 7(6), 380–389 (2005).
  • Poncet B, Bachelot T, Colin C et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am. J. Clin. Oncol.31(4), 363–368 (2008).
  • Poncet B, Colin C, Bachelot T et al. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab. Am. J. Clin. Oncol. 32(4), 369–374 (2009).
  • Purmonen TT, Auvinen PK, Martikainen JA. Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective. Int. J. Technol. Assess Health Care 26(2), 163–169 (2010).
  • Retèl VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur. J. Cancer 46(8), 1382–1391 (2010).
  • Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost–effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res. Treat. 109(3), 559–566 (2008).
  • Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health 12(5), 641–648 (2009).
  • Sloka JS, Hollett PD, Mathews M. Cost-effectiveness of positron emission tomography in breast cancer. Mol. Imaging Biol. 7(5), 351–360 (2005).
  • Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologis 15(5), 457-465 (2010).
  • Van Vlaenderen I, Canon JL, Cocquyt V et al. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta. Clin. Belg. 64(2), 100–112 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.